Beneficial Treatment Management with Trifluridine/Tipiracil in a Patient with Metastatic Colorectal Cancer and Pronounced Hematological Event History during Previous Treatments

Beneficial Treatment Management with Trifluridine/Tipiracil in a Patient with Metastatic Colorectal Cancer and Pronounced Hematological Event History during Previous Treatments

Trifluridine/tipiracil (FTD/TPI) significantly improves overall survival in patients with metastatic colorectal cancer (mCRC). The most common treatment-related event (grade ≥3) was hematological toxicity. We here report long-term disease-stabilizing FTD/TPI treatment of an mCRC patient (KRAS wild-t...

Full description

Bibliographic Details
Main Authors: Volker Kaechele, Jürgen Hess, Wolfgang Schneider-Kappus
Format: Article
Language:English
Published: Karger Publishers 2018-01-01
Series:Case Reports in Oncology
Subjects:
Colorectal cancer
Chemotherapy
Trifluridine/tipiracil
Dose reduction
Myelosuppression
Granulocyte colony-stimulating factor
Hemotoxicity
Online Access:https://www.karger.com/Article/FullText/486195

Internet

https://www.karger.com/Article/FullText/486195

Similar Items